Insmed INC Form 4 insider transactions

INSMED Director Melvin Sharoky reported gifting 100 shares of common stock on March 3, 2026, maintaining significant direct and indirect beneficial ownership.

INSMED Inc. Director Melvin Sharoky reported gifting 1,072 shares of common stock, with 972 shares transferred to family UTMA/FL accounts where he serves as custodian.

INSMED's Chief Legal Officer, Michael Alexander Smith, exercised stock options and subsequently sold a significant portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.

INSMED Inc. Director David R. Brennan reported gifting 6,000 shares of common stock on February 23, 2026, as part of a pre-planned transaction.

INSMED Inc.'s Chair and CEO, William Lewis, exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged 10b5-1 trading plan.

INSMED Director David W.J. McGirr reported gifting 53,400 shares of common stock to a family trust, effective February 9, 2026.

INSMED Inc.'s Chair and CEO, William Lewis, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.

INSMED's Chief Medical Officer, Martina Flammer, sold 869 shares of common stock for $152.44 per share, executed under a pre-arranged 10b5-1 trading plan.

INSMED Inc.'s Chief Operating Officer, Roger Adsett, sold 791 shares of common stock to cover tax withholding obligations and broker fees.

INSMED Inc.'s Chief Financial Officer, Sara Bonstein, sold 748 shares of common stock to cover tax withholding obligations and broker fees.

INSMED Inc.'s Chair and CEO, William Lewis, reported the sale of 3,009 common shares to cover tax withholding obligations.

INSMED's Chief Legal Officer, Michael Alexander Smith, sold 640 shares of common stock to cover tax withholding obligations and broker fees.

INSMED's Chief Medical Officer, Martina Flammer, exercised stock options and subsequently sold a portion of her common stock holdings.

INSMED Inc.'s Chair and CEO, William Lewis, exercised stock options and subsequently sold an equal number of common shares on January 20, 2026, as part of a pre-arranged 10b5-1 trading plan.

INSMED Inc. Chair and CEO William Lewis exercised stock options and subsequently sold a portion of his common stock holdings on January 12, 2026, under a pre-arranged 10b5-1 trading plan.

INSMED's Chief Medical Officer, Martina M.D. Flammer, sold 1,887 shares of common stock for $186.19 per share under a pre-arranged 10b5-1 trading plan.

INSMED's Chief Operating Officer, Roger Adsett, sold common stock totaling 4,290 shares across three transactions in early January 2026 to cover tax withholding obligations and broker fees.

INSMED Inc.'s Chief Financial Officer, Sara Bonstein, sold shares of common stock totaling 4,642 units over three days in January 2026 to cover tax withholding and broker fees.

INSMED's Chief Medical Officer, Martina M.D. Flammer, reported exercising stock options and subsequently selling a significant number of common shares.

INSMED Inc.'s Chair and CEO, William Lewis, sold common stock totaling 9,676 shares across three transactions in early January 2026 to cover tax withholding obligations and broker fees related to vested Restricted Stock Units.

INSMED's Chief Legal Officer, Michael Alexander Smith, sold common stock totaling 3,158 shares across three transactions in early January 2026 to cover tax withholding obligations and broker fees.

INSMED's Chief Medical Officer, Martina M.D. Flammer, reported the acquisition of new equity awards and the exercise and sale of shares under a pre-arranged 10b5-1 trading plan.

INSMED Inc.'s Chief Financial Officer, Sara Bonstein, was granted 11,643 Restricted Stock Units and 31,280 stock options under the company's incentive plan.

INSMED Inc.'s Chair and CEO, William Lewis, reported the acquisition of 21,172 Restricted Stock Units and 110,400 stock options as part of the company's incentive plan.

INSMED Inc.'s Chief Operating Officer, Roger Adsett, was granted 5,998 Restricted Stock Units and 31,280 stock options on January 2, 2026, as part of the company's incentive plan.

INSMED Inc.'s Chief Legal Officer, Michael Alexander Smith, was granted 5,293 Restricted Stock Units and 27,600 stock options on January 2, 2026, as part of the company's incentive plan.

INSMED's Chief People Strategy Officer reported the exercise and sale of common stock, alongside new RSU and option grants, all executed under a pre-arranged 10b5-1 plan.

INSMED Inc. CEO William Lewis exercised stock options and simultaneously sold an equal number of common shares under a pre-arranged 10b5-1 trading plan.

INSMED Director Melvin Sharoky sold 20,000 shares of common stock for approximately $4.1 million under a pre-arranged trading plan.

INSMED Inc.'s Chair and CEO, William Lewis, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.